Open an account

Damora Therapeutics

DMRA · NASDAQ

$20.67+$1.40 (+7.27%)TodayMarket closed ·
Prev close $19.27

About DMRA

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2020-10-29. The firm is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. The company offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.

Employees
7
Headquarters
Waltham, Massachusetts
Listed
Oct 29, 2020
Sector
Health Care
Industry
Biotechnology
Website
galecto.com

DMRA key statistics

Market cap
1.28B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
578.99K
Volume
242.33K
Open price
$19.30
High today
$20.92
Low today
$19.30
52 Week high
$38.33
52 Week low
$4.95

Damora Therapeutics (DMRA) at a glance

As of Oct 20, 2026, Damora Therapeutics (DMRA) shares are priced at $20.67, giving the company a market cap of 1.28B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.30 and $20.92. The current price is 7.1% above the day's low and 1.2% below its high.

Volume so far is 242.33K shares, below the average of 578.99K shares a day.

Over the past year Damora Therapeutics has ranged from $4.95 to $38.33, and now sits 47% of the way up that range.

Damora Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.39 per share against an estimate of -$0.4342.

The average analyst price target is $47.83, 131.4% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $47.83
Low
$40.40
Now
$20.67
High
$63.00

DMRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 456.2% on average.

  1. Q4 FY23: reported -$6.00 per share against an estimate of -$7.87
  2. Q1 FY24: reported -$5.00 per share against an estimate of -$10.45
  3. Q2 FY24: reported -$4.00 per share against an estimate of -$8.03
  4. Q3 FY24: reported -$3.39 per share against an estimate of -$4.18
  5. Q4 FY24: reported -$5.23 per share against an estimate of -$3.03
  6. Q4 FY25: reported $2.70 per share against an estimate of -$0.1088
  7. Q1 FY26: reported -$0.62 per share against an estimate of -$0.3953
  8. Q2 FY26: reported -$0.39 per share against an estimate of -$0.4342

DMRA news

  • Press releaseGlobe Newswire

    Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Damora Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.